ADPTNMSHealthcare·Biotechnology#100 in industry

Adaptive Biotechnologies Corporation

Reports in 8d· 2026-05-05

-26.1% · 90d

$14.21

+0.07 (+0.50%)

After-Hours $14.21(+0.00)

News

No News Yet

Press releases and SEC filings for ADPT will appear here as they are published.

Check back later for updates

Key Data

Market Cap$2.19B

Open$14.03

Prev Close$14.14

Day Range$14.03 – $14.36

52W Range$7.16 – $20.76

Volume1,029,787

P/E (TTM)—

EPS$-0.39

Dividend Yield—

Beta2.30

Profit Margin-21.48%

Revenue Growth51.00%

Price Target$20.57(+44.8%)

Next Earnings2026-05-05(8d)

Analyst Ratings

Strong Buy8 analysts

Buy 7Hold 1Sell 0

About

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Healthcare · Biotechnology

624 employees

www.adaptivebiotech.com